Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2025 Revenue

About this update from Standard Biotools Inc.

[{"type":"image","alt":"Standard BioTools Inc.","displaySize":"","headline":null,"caption":"Standard BioTools Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":214,"url":"https://media.zenfs.com/en/globenewswire.com/62bb817180017915a417644b36a1d053"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/fFQS13CdQZEX2RHrMp.CBg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTMwMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/62bb817180017915a417644b36a1d053","width":300,"height":214}},"lazy":false},{"type":"text","content":"Preliminary, unaudited combined company revenue for the full year 2025 of approximately $185 million; Revenue from continuing operations of approximately $85 million","length":165,"tagName":"p"},{"type":"text","content":"BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (“Standard BioTools” or the “Company”) today announced preliminary and unaudited revenue results for the fourth quarter and full year 2025. Standard BioTools expects fourth quarter 2025 combined company revenue of approximately $56 million and revenue from continuing operations of approximately $24 million. For the full year 2025, the Company expects combined company revenue of approximately $185 million and revenue from continued operations of approximately $85 million.","length":554,"tagName":"p"},{"type":"text","content":""Our 2025 performance reflected steady execution, ending the year above our guidance range and exceeding expectations for both combined and continuing operations,” said Michael Egholm, PhD, Chief Executive Officer of Standard BioTools. “Amid a shifting macro backdrop, the team remained focused – managing what we could control to drive the business forward.”","length":364,"tagName":"p"},{"type":"text","content":"Dr. Egholm added, “We continued our path toward profitability, taking targeted actions to streamline the organization and sharpen our operating model. Grounded in continuous improvement, we optimized workflows, improved our cost structure and drove rigor across the Company. These efforts strengthened our foundation and leave us exiting the year a leaner organization and a more resilient business.”","length":400,"tagName":"p"},{"type":"text","content":"“As we look to 2026, the sale of SomaLogic to Illumina remains on track to close in the first half of the year. At close, we ex...

More updates from Standard Biotools Inc.